Prostate Cancer
PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
October 23, 2023
Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.
October 23, 2023
Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: A Canadian bicentric study and comparison with 2010 data.
October 23, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
October 20, 2023
Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade.
October 20, 2023
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
October 19, 2023
Comparative analysis of robot-assisted and open approach for PSMA-radioguided surgery in recurrent prostate cancer.
October 19, 2023
Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.
October 19, 2023
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
October 18, 2023
Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile.
October 18, 2023